Inclusion Criteria:

          1. Willing and able to provide signed and dated informed consent

          2. Patients with histologically or cytologically confirmed, locally advanced or
             metastatic solid tumors, evaluable by RECIST v1.1. (Part B includes metastatic HPV+
             malignancies)

          3. Subject who has tumor progression during or after prior therapy and for whom no
             standard therapy exists that would confer clinical benefit.

          4. At least one measurable lesion per RECIST 1.1 (Part B only).

          5. Eastern Cooperative Oncology Group Performance Status (ECOG PS)0~1.

          6. Provide archived tumor tissue samples

          7. Adequate organ function

        Exclusion Criteria:

          1. Concurrent malignancy within 3 years prior to entry other than adequately treated
             cervical carcinoma-in-situ, localized squamous cell cancer of the skin, basal cell
             carcinoma, prostate cancer not requiring treatment (with or without resection), ductal
             carcinoma in situ of the breast, or ≤ T1 urothelial carcinoma.

          2. Untreated or symptomatic central nervous system (CNS) metastases.

          3. Any unresolved Grade 2 or greater toxicity from previous anticancer therapy except
             alopecia.

          4. Active leptomeningeal disease.

          5. Active autoimmune diseases or history of autoimmune diseases that may relapse, with
             the following exceptions:

               -  Controlled type 1 diabetes

               -  Hypothyroidism (provided it is managed with hormone-replacement therapy only)

               -  Controlled celiac disease

               -  Skin diseases not requiring systemic treatment (eg, vitiligo, psoriasis, or
                  alopecia)

               -  Any other disease that is not expected to recur in the absence of external
                  triggering factors

          6. Any condition that required systemic treatment with either corticosteroids (> 10 mg
             daily of prednisone or equivalent) or other immunosuppressive medication ≤ 14 days
             before the first dose of investigational product, with the following exceptions:

               -  Adrenal replacement steroid (dose ≤ 10 mg daily of prednisone or equivalent)

               -  Topical, ocular, intra-articular, intranasal, or inhalational corticosteroid with
                  minimal systemic absorption

               -  Short course (≤ 7 days) of corticosteroid prescribed prophylactically (eg, for
                  contrast dye allergy) or for the treatment of a non-autoimmune condition (eg,
                  delayed-type hypersensitivity reaction caused by contact allergen)

          7. History of interstitial lung disease, noninfectious pneumonitis, or uncontrolled lung
             diseases, including but not limited to pulmonary fibrosis, active pneumonitis.

          8. Severe cardiovascular disease, including cerebrovascular accident, transient ischemic
             attack, myocardial infarction, or unstable angina, New York Heart Association class
             III or IV heart failure or uncontrolled arrhythmia within 6 months of first dose.

          9. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic
             therapy within 2 weeks of screening.

         10. Clinically significant bleeding within three months of the first dose.

         11. Uncontrolled hypertension, defined as systolic ≥150 mm Hg or diastolic ≥90 mm Hg
             maintained over time and despite antihypertensive treatment.

         12. Patients with QTcF > 480 ms on screening ECG or with a history of additional risk
             factors for TdP (e.g., heart failure, hypokalemia，family history of Long QT Syndrome)

         13. Pregnant or nursing.

         14. Known human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome.

         15. A serious nonmalignant disease (e.g., psychiatric, substance abuse, uncontrolled
             intercurrent illness, etc.) that could compromise protocol objectives in the opinion
             of the Investigator and/or the Sponsor.

         16. Any other condition that, in the opinion of the Investigator, would prohibit the
             subject from participating in the study.

         17. Active autoimmune disease requiring systemic therapy in the last 2 years prior to the
             first dose (i.e., with use of disease modifying agents, systemic corticosteroids or
             immunosuppressive drug).

             • Subjects with Type 1 diabetes mellitus (TD1M), hypothyroidism requiring only hormone
             replacement, or skin disorders not requiring systemic treatment are permitted to
             enroll.

         18. A history of (non-infectious) pneumonitis that required steroids or has current
             pneumonitis.

         19. < 4 weeks after any major procedures/surgery; clinically significant unhealed wound;
             any unhealed ulceration in GI prior to first dose of TST005.

         20. History of severe immune-related adverse effects from checkpoint inhibitor (CPI)
             therapy (NCI CTCAE Grade 3 or 4) with the exception of endocrinopathy managed with
             replacement therapy or subjects who discontinued CPI therapy for CPI-associated
             toxicity or intolerability.